Year : 2018 | Volume
: 10 | Issue : 4 | Page : 363--369
Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?
Serife Solmaz1, Ozcan Uzun2, Celal Acar1, Omur Gokmen Sevindik3, Ozden Piskin4, Hayri Guner Ozsan4, Fatih Demirkan4, Bulent Undar4, Ahmet Alacacioglu5, Mehmet Ali Ozcan4, Inci Alacacioglu4
1 Department of Hematology, Bozyaka Education and Research Hospital, Batman, Turkey
2 Department of Internal Medicine, Batman Education and Research Hospital, Batman, Turkey
3 Department of Hematology, Faculty of Medicine, Medipol Universıty, Istanbul, Turkey
4 Department of Hematology, Faculty of Medicine, Dokuz Eylul Universıty, Izmir, Turkey
5 Faculty of Oncology, Katip Çelebi University, Izmir, Turkey
BACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies.
MATERIALS AND METHODS: We retrospectively examined the PLR, NLR, and MLR in a cohort of 186 newly diagnosed multiple myeloma (MM) patients. This study investigated the prognostic relevance of NLR, PLR, and MLR in MM patients. NLR, PLR, and MLR were calculated from whole blood counts before therapy. The Kaplan–Meier curves and multivariate Cox models were used for the evaluation of survival.
RESULTS: Applying cutoff of 1.9 (NLR), 120.00 (PLR), and 0.27 (MLR), decreased PLR showed a negative impact on the outcome. Decreased PLR is an independent predictor for PFS and OS. There were no significant differences in median survival between the high and low NLR (P = 0.80) and MLR (P = 0.87) groups.
CONCLUSIONS: In this study, thrombocytopenia and low PLR are associated with poor survival in MM patients does this P value apply to thrombocytopenia or low PLR and may serve as the cost-effective prognostic biomarker.
Dr. Serife Solmaz
Izmir Bozyaka Education and Research Hospital, Hematology, Izmir
|How to cite this article:|
Solmaz S, Uzun O, Acar C, Sevindik OG, Piskin O, Ozsan HG, Demirkan F, Undar B, Alacacioglu A, Ozcan MA, Alacacioglu I. Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?.J Lab Physicians 2018;10:363-369
|How to cite this URL:|
Solmaz S, Uzun O, Acar C, Sevindik OG, Piskin O, Ozsan HG, Demirkan F, Undar B, Alacacioglu A, Ozcan MA, Alacacioglu I. Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?. J Lab Physicians [serial online] 2018 [cited 2019 Mar 23 ];10:363-369
Available from: http://www.jlponline.org/article.asp?issn=0974-2727;year=2018;volume=10;issue=4;spage=363;epage=369;aulast=Solmaz;type=0